InVivoMAb anti-mouse CTLA-4 (CD152)

Zippelius A, Schreiner J, Herzig P, et al. Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment. Cancer Immunol Res. 2015,3(3):236-44. doi: 10.1158/2326-6066.CIR-14-0226

Dai M, Yip YY, Hellstrom I, et al. Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies. Clin Cancer Res. 2015,21(5):1127-38. doi: 10.1158/1078-0432.CCR-14-1339

Müller P, Martin K, Theurich S, et al. Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells. Cancer Immunol Res. 2014,2(8):741-55. doi: 10.1158/2326-6066.CIR-13-0198

Condamine T, Kumar V, Ramachandran IR, et al. ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. J Clin Invest. 2014,124(6):2626-39. doi: 10.1172/JCI74056

Redmond WL, Linch SN, Kasiewicz MJ. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity. Cancer Immunol Res. 2014,2(2):142-53. doi: 10.1158/2326-6066.CIR-13-0031-T

Wei H, Zhao L, Li W, et al. Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin. PLoS One. 2013,8(12):e84927. doi: 10.1371/journal.pone.0084927

Bulliard Y, Jolicoeur R, Windman M, et al. Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med. 2013,210(9):1685-93. doi: 10.1084/jem.20130573

Dai M, Wei H, Yip YY, et al. Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation. J Immunother. 2013,36(4):248-57. doi: 10.1097/CJI.0b013e3182943549

Hooijkaas A, Gadiot J, Morrow M, et al. Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma. Oncoimmunology. 2012,1(5):609-617.

Balachandran VP, Cavnar MJ, Zeng S, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med. 2011,17(9):1094-100. doi: 10.1038/nm.2438